Security
Skinvisible, Inc. Common Stock · SKVI
SKVIOTCCommon stockHistorical · closed Jan 4, 2019CIK 1085277Updated Nov 17, 2026
SKVI price & chart
This listing closed Jan 4, 2019. Live provider charts are shown only for current listings.
Current security: SKVI
About the company
Inc. Skinvisible Pharmaceuticals, a wholly-owned subsidiary of Skinvisible, Inc., is a pioneering research and development company specializing in licensing proprietary topical and transdermal formulations utilizing its patented polymer skin delivery system; Invisicare. This innovative technology provides life-cycle management and distinctive enhancements for both topical and transdermal delivery products. Invisicare formulated as a lotion or cream, effectively adheres active ingredients to the skin facilitating a controlled release of the active to and/or through the skin and into the blood stream over time. Skinvisible has recently developed formulations for the potential treatment of obesity, along with over forty dermatology related conditions including rare skin disorders. For further details, please visit www.skinvisible.com.
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 133,623Source | 148,643Source | 123,334Source | 143,375Source | 163,058Source | 119,419Source | 149,554Source | 153,403Source | 127,567Source | 158,217Source | 162,869Source | 246,793Source |
| Current assets: | ||||||||||||
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 5,000Source | 1,000Source | 5,000Source | 5,000Source | 5,000Source | 5,000Source | 470Source | — | 5,000Source | 5,000Source | 5,000Source | — |
| Assets, CurrentUSD | 28,469Source | 27,404Source | 33,301Source | 33,102Source | 35,882Source | 24,390Source | 38,305Source | 30,689Source | 27,531Source | 42,028Source | 35,460Source | 109,946Source |
| Prepaid Expense and Other Assets, CurrentUSD | 5,232Source | 4,200Source | 6,750Source | 10,390Source | 6,300Source | — | 6,847Source | — | 2,319Source | 9,100Source | 7,980Source | 9,495Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 10,138,047Source | 10,016,111Source | 10,908,832Source | 9,897,554Source | 9,744,922Source | 10,649,384Source | 9,629,306Source | 9,466,818Source | 10,390,348Source | 9,404,164Source | 9,185,912Source | 6,887,396Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 5,404Source | 4,890Source | 5,404Source | 5,404Source | 4,890Source | 5,404Source | 5,404Source | 4,540Source | 5,404Source | 5,317Source | 4,540Source | 4,540Source |
| Additional Paid in CapitalUSD | 30,741,991Source | 30,387,555Source | 30,741,991Source | 30,741,991Source | 30,387,555Source | 30,741,991Source | 30,741,991Source | 30,352,905Source | 30,741,991Source | 30,684,878Source | 30,352,905Source | 30,352,905Source |
| Retained Earnings (Accumulated Deficit)USD | -40,751,819Source | -40,260,913Source | -41,532,893Source | -40,501,574Source | -39,974,309Source | -41,277,360Source | -40,227,147Source | -39,670,860Source | -41,010,176Source | -39,946,142Source | -39,380,488Source | -36,998,048Source |
| Stockholders' Equity Attributable to ParentUSD | -10,004,424Source | -9,867,468Source | -10,785,498Source | -9,754,179Source | -9,581,864Source | -10,529,965Source | -9,479,752Source | -9,313,415Source | -10,262,781Source | -9,245,947Source | -9,023,043Source | -6,640,603Source |
| Liabilities and EquityUSD | 133,623Source | 148,643Source | 123,334Source | 143,375Source | 163,058Source | 119,419Source | 149,554Source | 153,403Source | 127,567Source | 158,217Source | 162,869Source | 246,793Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 4,765,644Source | 4,643,708Source | 5,536,429Source | 4,525,151Source | 4,023,571Source | 5,276,981Source | 4,256,903Source | 4,094,415Source | 5,017,945Source | 3,679,686Source | 3,512,407Source | 3,644,986Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation and amortization | — | — | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source | —Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | — | 4,530Source | — | — | — | -18,991Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -822Source | -31,720Source | -38,410Source | -69,834Source | -77,157Source | 45,170Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | — | — | -4,086Source | -9,218Source | -9,333Source | -2,530Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | — | 34,780Source | 34,780Source | 88,500Source | 6,000Source | -27,299Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -822Source | 3,060Source | -7,716Source | 9,448Source | -80,490Source | 15,341Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 645Source | 612Source | 3,959Source | 120Source | 1,798Source | 13,396Source | 2,620Source | 10,336Source | 888Source | 81,378Source |
| Additional Financial Items | ||||||||||||
| Amortization of Debt Issuance Costs and DiscountsUSD | — | — | — | — | — | — | — | — | — | 50,973Source | 1,278,901Source | 660,686Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | — | — | 697,249Source | — | 144,379Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -250,245Source | -286,604Source | -255,533Source | -274,427Source | -267,184Source | -281,005Source | -1,064,034Source | -565,654Source | -2,382,440Source | -1,224,887Source |
| Operating ExpensesUSD | — | — | 111,057Source | 129,969Source | 117,817Source | 141,237Source | 130,938Source | 144,852Source | 516,315Source | 609,589Source | 510,375Source | 512,920Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | 24,780Source | 24,780Source | — | — | — |
| Unrealized Gain (Loss) on DerivativesUSD | — | — | — | 6,122Source | — | — | — | — | — | -3,876Source | -4,915Source | 32,035Source |
| Amortization of Intangible Assets | — | — | — | — | — | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 5,000Source | 5,000Source | 5,000Source | 5,000Source | 5,000Source | 5,000Source | 20,000Source | 20,000Source | 20,000Source | 279,296Source |
| Cost of Goods and Services Sold | — | — | — | — | — | — | — | — | — | — | — | —Source |
| Selling, General and Administrative ExpenseUSD | — | — | 105,939Source | 124,032Source | 112,821Source | 136,174Source | 125,931Source | 139,912Source | 496,076Source | 589,151Source | 491,604Source | 494,182Source |
| Operating Income (Loss)USD | — | — | -106,057Source | -124,969Source | -112,817Source | -136,237Source | -125,938Source | -139,852Source | -496,315Source | -589,589Source | -490,375Source | -238,432Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -250,245Source | -286,604Source | -255,533Source | -274,427Source | -267,184Source | -281,005Source | -1,064,034Source | -565,654Source | -2,382,440Source | -1,224,887Source |
| Earnings Per Share, DilutedUSD per share | — | — | — | -0.06Source | — | — | — | — | — | -0.11Source | -0.52Source | -0.27Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 5,403,843Source | 4,539,843Source | 5,403,843Source | 5,403,843Source | 5,403,843Source | 5,362,787Source | 5,393,805Source | 5,061,350Source | 4,539,843Source | 4,539,843Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | — | 4,539,843Source | — | — | — | — | — | 5,061,350Source | 4,539,843Source | 4,539,843Source |
| Additional Financial Items | ||||||||||||
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | 5,118Source | 5,937Source | 4,996Source | 5,063Source | 5,007Source | 4,940Source | 20,239Source | 20,438Source | 18,771Source | 18,738Source |
| Gross ProfitUSD | — | — | 5,000Source | 5,000Source | 5,000Source | 5,000Source | 5,000Source | 5,000Source | 20,000Source | 20,000Source | 20,000Source | 274,488Source |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | — | — | -0.05Source | -0.06Source | -0.05Source | -0.05Source | -0.05Source | -0.05Source | -0.2Source | -0.11Source | -0.52Source | -0.27Source |
| Interest ExpenseUSD | — | — | 144,188Source | 167,757Source | 142,716Source | 142,720Source | 141,246Source | 141,153Source | 572,249Source | 669,438Source | 1,887,150Source | 1,162,869Source |
| Operating ExpensesUSD | — | — | 111,057Source | 129,969Source | 117,817Source | 141,237Source | 130,938Source | 144,852Source | 516,315Source | 609,589Source | 510,375Source | 512,920Source |
| Other ExpensesUSD | — | — | 144,188Source | 161,635Source | 142,716Source | 138,190Source | 141,246Source | 141,153Source | 567,719Source | -23,935Source | 1,892,065Source | 986,455Source |
| Other IncomeUSD | — | — | — | — | — | 4,530Source | — | — | 4,530Source | — | — | — |
| Amortization of Intangible Assets | — | — | — | — | — | — | — | — | — | — | — | — |
Filing attachments
ex99_1.htm · 8-K · 2025-01-23
EX-99.1 5 ex99_1.htm PRESS RELEASE, DATED JANUARY 23, 2025 Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies Topic: Company Update Thursday, 23 January 2025 05:30 AM LAS VEGAS, NV / ACCESS Newswire / January 23, 2025 / Skinvisible Pharmaceuticals, Inc. ("Skinvisible" or "the Company"), (OTCQB: SKVI ), an innovative topical and transdermal pharmaceutical research and development company, with proprietary Invisicare® drug delivery technology, today announces signi…
Read attachment ↗